Hurricanes worsen outcomes for lung cancer radiotherapy

Lung cancer patients undergoing radiotherapy during the time of a declared...Read more on AuntMinnie.comRelated Reading: Single-dose brachytherapy treats low-risk prostate cancer ASTRO: Prior authorization delays radiation treatment SABR plus surgery is effective for treating lung cancer Shorter radiotherapy works for prostate cancer treatment ASTRO updates guideline for lung cancer radiation therapy
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Authors: Chen P, Wang H, Li M, Yang L, Mou F, Singh B, He JY, Zhang W Abstract 6,12-Diphenyl-3,9-diazatetraasterane-1, 5, 7, 11-tetracarboxylate (DDTC) has been synthesized by the photodimerization of 4-phenyl-1,4-dihydropyridine-3,5-dicarboxylate. The potential of theercvantitumor activity and mechanism were investigated in vitro using MTT assay in human lung cancer cell line A549, ovarian cancer cell lines SKOV3 and A2780, breast cancer cell line MCF-7, gastric cancer cell line BGC-823, colon cancer cell line HT29, prostate cancer cell line DU145, and liver cancer cell line SMMC7721. The results show that DDTC ca...
Source: Disease Markers - Category: Laboratory Medicine Tags: Dis Markers Source Type: research
Radiology reports created with help from artificial intelligence (AI) are more...Read more on AuntMinnie.comRelated Reading: C-MIMI: AI peer review can spot missed lung cancer C-MIMI: Use of AI in radiology is evolving SNMMI 2020: AI analysis of PET could help classify prostate cancer SIIM 2020: Human element shouldn't be neglected with AI AI Metrics joins forces with Imaging Biometrics
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Cancers, Vol. 12, Pages 2654: Analysis of Bone Scans in Various Tumor Entities Using a Deep-Learning-Based Artificial Neural Network Algorithm—Evaluation of Diagnostic Performance Cancers doi: 10.3390/cancers12092654 Authors: Jan Wuestemann Sebastian Hupfeld Dennis Kupitz Philipp Genseke Simone Schenke Maciej Pech Michael C. Kreissl Oliver S. Grosser The bone scan index (BSI), initially introduced for metastatic prostate cancer, quantifies the osseous tumor load from planar bone scans. Following the basic idea of radiomics, this method incorporates specific deep-learning techniques (artificial n...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
A research team at Oslo University Hospital in Norway has opened a mesothelioma clinical trial using the novel UV1 cancer vaccine alongside a promising immunotherapy combination. UV1 is a peptide-based vaccine designed to induce a specific T-cell response and increase the effectiveness of the immunotherapy drugs. This is the first time UV1 will be studied with mesothelioma cancer, but it already has shown safety and signs of efficacy when used on malignant melanoma, prostate cancer and lung cancer in studies worldwide. It will be used with the immunotherapy combination of nivolumab and ipilimumab, also known by brand names...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSION: Our findings were consistent with findings from other studies showing that the incidence rate of cancer differs across levels of socioeconomic status. We may need behavioral change campaigns focused on lifestyle changes that lower the risk of cancer and target perhaps to those with lower socioeconomic status. PMID: 32924698 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Lung cancer is the second most prevalent cancer in the US, and the deadliest cancer killer. In 2020, an estimated 135,720 people will die from the disease — more than breast, colon, and prostate cancers combined. I’ll never forget meeting new, advanced-stage lung cancer patients who ask if their diagnosis could have somehow been made earlier, when treatment would have been more likely to succeed. In 2009, when I began practicing thoracic oncology, there were no approved screening tests for lung cancer. A brief history of lung cancer screening Hope for early detection and death prevention came in 2011 with the p...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cancer Lung disease Screening Source Type: blogs
Bayer to showcase new data from evolving Oncology portfolio at ESMO Virtual Congress 2020Long-term efficacy and safety results for larotrectinib (Vitrakvi™) from an integrated data set of adult and pediatric patients with TRK fusion cancer, as well as sub-analyses in advanced thyroid and lung cancer patients / Tolerability and treatment response data from the Phase III ARAMIS trial investigating darolutamide (Nubeqa™) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Continued research to explore potential of marketed products, evaluating regorafenib (Stivarga™) and radium-223 dic...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news
Conclusions: Our findings demonstrate that on account of the dual function of pro-proliferation and anti-apoptosis, PCAT-1/miR-324-5p/RAP1A may be novel candidates for application in the diagnosis, prognosis and therapy of lung cancer. PMID: 32864009 [PubMed]
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Brachytherapy | Cancer | Cancer & Oncology | Lung Cancer | Prostate Cancer | Radiation Therapy | Radiology